

RADIOTRACERS TO DETECT EARLY PARKINSON'S DISEASE

[Kotzbauer, Paul](#), [Qiu, Lin](#), [Tu, Zhude "Will"](#), [Yu, Yanbo](#)

[Gill, John](#)


T-020559

Radiotracers to detect early Parkinson's disease

Technology Description

Researchers at Washington University in St. Louis, led by Dr. Zhude Tu, have developed two imaging agents for α -synuclein (α -syn) aggregation for use to diagnose early Parkinson's disease, track disease progression, and assess efficacy of disease-modifying therapies. Data showed these imaging agents had high brain uptake, suitable brain washout pharmacokinetics, and, more importantly, no presence of lipophilic radio-metabolites in the brain confounding the PET measurement.

The aggregation of misfolded α -syn is a pathological hallmark of Parkinson's disease; however, no reliable imaging biomarker is currently available for α -syn.



Above: PET characterization of radioligands in the macaque brain. Left: Time-activity curve for microPET study in the brain, SUV: standardized uptake value; Right: Representative PET images of two radiotracers in the macaque brain, weighted average of 0-120 min.

Stage of Research

- Proof of concept has been demonstrated *in vivo* with murine and non-human primate models

Publications

- Yanbo Yu, *et al.*, [Radiosynthesis and biological evaluation of two \$^{18}\text{F}\$ -labeled PET radioligands for \$\alpha\$ -synuclein](#). JNM, Vol. 64, Issue supplement 1, (2023)

Applications

- Diagnostic for early Parkinson's disease
- Together, these agents with high potency and selectivity for α -syn have great potential to being a therapeutic drug that targets α -syn

Key Advantages

- **Early diagnosis, specific, crosses blood-brain barrier, favorable washout kinetics**

Patents

- Pending

Related Web Links

- Dr. Zhude Tu, [Profile](#)